97055 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Receptors; Cell surface antigens; Cell surface determinants Molecules with a "CD"-designation not provided for elsewhere
PRODUCTION OF EXOSOMES AND USES THEREOF
#302Methods for treating cancer using soluble forms of PSGL-1 and fusion molecules thereof
#303METHODS OF SENSITIZING CANCER TO IMMUNOTHERAPY
#304PD-1 VARIANTS HAVING INCREASED PD-L1 AFFINITY
#305PROSTATE SPECIFIC MEMBRANE ANTIGEN BINDING FIBRONECTIN TYPE III DOMAINS AND CELLS COMPRISING THE SAME
#306BOTTOM-UP ASSEMBLY OF SYNTHETIC EXTRACELLULAR VESICLES
#307PD-L1 variants with improved affinity towards PD-1
#308GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD94 AND/OR NKG2A
#309IMMUNOCYTOKINES AND USES THEREOF
#310Composition for preventing or treating diseases caused by overexpression of chemokine CXCL1, containing death receptor inhibitor as active ingredient
#311CHIMERIC POLYPEPTIDE FOR REGULATING IMMUNE CELLS
#312GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD38
#313Fusion Protein Extensions
#314CD24-LOADED VESICLES FOR TREATMENT OF CYTOKINE STORM AND OTHER CONDITIONS
#315COMPOSITIONS AND METHODS FOR TREATING DISEASES AND CONDITIONS BY DEPLETION OF MITOCHONDRIAL OR GENOMIC DNA FROM CIRCULATION
#316Immune synapse-stabilizing chimeric antigen receptor (CAR) T cell
#317DETECTION OF NOVEL DEGRADATION-RELATED INTERACTIONS
#318CHIMERIC ANTIGEN RECEPTOR TARGETING B-CELL MATURATION ANTIGEN AND USE THEREOF
#319METHODS OF MAKING TOLEROGENIC DENDRITIC CELLS
#320THERAPEUTIC DELIVERY VESICLES
#321RECOMBINANT FUSION PROTEINS TARGETING CD47 AND CD38, PREPARATION AND USE THEREOF
#322COMPOSITIONS AND METHODS OF STIMULATING AND EXPANDING T CELLS
#323CHIMERIC SCAVENGER RECEPTORS TARGETED TO PHOSPHORYLATED TAU (PTAU) AND USES THEREOF
#324METHODS OF USE OF SOLUBLE CD24 FOR TREATING VIRAL PNEUMONIA
#325METHODS FOR EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES AND USE THEREOF
#326METHODS FOR TREATING EYE DISEASE
#327METHODS FOR ENRICHING MARROW INFILTRATING LYMPHOCYTES ("MILS"), COMPOSITIONS CONTAINING ENRICHED MILS, AND METHODS OF USING ENRICHED MILS
#328Recombinant expression platform, constructs and methods for expression of Difficult to Express Proteins (DTE-Ps)
#329A MIXTURE OF MRNA TO ENHANCE THE POTENCY OF DENDRITIC CELLS
#330ENHANCEMENT OF CD47 BLOCKADE THERAPY BY PROTEASOME INHIBITORS
#331POLYNUCLEOTIDES FOR DISRUPTING IMMUNE CELL ACTIVITY AND METHODS OF USE THEREOF
#332COMPOSITIONS AND METHODS FOR USE IN IMMUNOTHERAPY
#333COMPOSITIONS AND METHODS FOR T CELL ENGINEERING
#334CANCER GENE THERAPY DRUG
#335METHODS AND COMPOSITIONS FOR TREATING DISEASE USING TARGETED FOXP3+CD4+ T CELLS AND CELLULAR SUICIDE AGENTS
#336GENETICALLY ENGINEERED HEMATOPOIETIC STEM CELLS AND USES THEREOF
#337CHIMERIC ANTIGEN RECEPTORS AND RELATED METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
#338ENGINEERED T CELLS
#339PSGL-1 MODULATORS AND USES THEREOF
#340REGULATORY T CELL MEDIATOR PROTEINS AND USES THEREOF
#341CELLS WITH INCREASED IMMUNO-REGULATORY PROPERTIES AND METHODS FOR THEIR USE AND MANUFACTURE
#342LIBRARY OF BARCODED EXTRACELLULAR VESICLES
#343ARTIFICIAL SYNAPSES
#344B-CELL ANTIBODY RECEPTOR AND USE THEREOF
#345CHIMERIC RECEPTOR PROTEINS AND USES THEREOF
#346Prame TCR Receptors And Uses Thereof
#347Platforms, compositions, and methods for therapeutic delivery
#348IMMORTALIZED CARDIAC STEM CELLS FOR CARDIAC REPAIR
#349ENGINEERED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
#350PDL1 peptides for use in cancer vaccines
#351GENERATION OF CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS FROM STEM CELLS AND THERAPEUTIC USES THEREOF
#352ENGINEERED NATURAL KILLER CELLS AND METHODS FOR USING THE SAME IN IMMUNOTHERAPY AND AUTOPHAGY INHIBITON TECHNIQUES
#353CHIMERIC ANTIGEN RECEPTOR COMPRISING ANTI C-MET ANTIBODY OR ANTIGEN BINDING FRAGMENT THEREOF, AND USE THEREOF
#354COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS
#355COMPOUND CHIMERIC ANTIGEN RECEPTOR (cCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS AND METHOD OF USE THEREOF
#356USE OF SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR LEVELS IN THE MANAGEMENT OF PATIENTS WITH CARDIOVASCULAR DISEASE
#357CD24-ASSOCIATED PARTICLES AND RELATED METHODS AND USES THEREOF
#358MULTIMERIC PROTEIN DOMAINS FOR MULTIFUNCTIONALITY AND ENHANCED SECRETION OF THERAPEUTIC PROTEINS
#359CD33 TARGETED IMMUNOTHERAPIES
#360PEPTIDE ANTIGENS AND USES THEREOF
#361ANTIGEN-BINDING AGENTS THAT SPECIFICALLY BIND EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III
#362Methods of making and using extracellular domain-based chimeric proteins
#363PLATFORM FOR ENHANCED TARGETED CELL DELIVERY
#364CHIMERIC ANTIGEN RECEPTOR COMPRISING CD40 CYTOPLASMIC DOMAIN AND USES THEREOF
#365METHODS AND COMPOSITIONS FOR GENETICALLY MODIFYING LYMPHOCYTES TO EXPRESS POLYPEPTIDES COMPRISING THE INTRACELLULAR DOMAIN OF CD79A AND CD79B
#366ENGINEERED T CELLS AND USES THEREFOR
#367CHIMERIC ORTHOGONAL RECEPTOR PROTEINS AND METHODS OF USE
#368Compositions and Methods for Modulation of Gene Expression
#369NOVEL IL-21 PRODRUGS AND METHODS OF USE THEREOF
#370BIOMARKERS FOR CD47 BLOCKADE THERAPY
#371MULTISPECIFIC AND MULTIFUNCTIONAL MOLECULES AND USES THEREOF
#372RECOMBINANT ONCOLYTIC VIRUS, SYNTHETIC DNA SEQUENCE, AND APPLICATION THEREOF
#373Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof
#374FORMULATION CONTAINING TLR AGONIST AND METHODS OF USE
#375MODIFIED MULTIMERIC BICYCLIC PEPTIDE LIGANDS
#376Treating myelin diseases with optimized cell preparations
#377CELLS, TISSUES, ORGANS, AND/OR ANIMALS HAVING ONE OR MORE MODIFIED GENES FOR ENHANCED XENOGRAFT SURVIVAL AND/OR TOLERANCE
#378HETERODIMERS AND METHODS OF USE THEREOF
#379Antigen binding molecules comprising a trimeric TNF family ligand and encoding polynucleotides thereof
#380ANTIGEN BINDING MOLECULES COMPRISING A TNF FAMILY LIGAND TRIMER
#381ANTIGEN BINDING MOLECULES COMPRISING A TNF FAMILY LIGAND TRIMER
#382CD137 binding fibronectin type III domains
#383CD80 and CD86 Binding Protein Compositions and Uses Thereof
#384CD80 and CD86 binding protein compositions and uses thereof
#385FORMULATION CONTAINING TLR AGONIST AND METHODS OF USE
#386EXTRACELLULAR VESICLES TARGETING T CELLS AND USES THEREOF
#387FUSION PROTEIN AND USE THEREOF
#388Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof
#389ANTI-DLL3 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
#390MEMBRANE PROTEIN SCAFFOLDS FOR EXOSOME ENGINEERING
#391TRANSGENIC CLONED PIG FOR XENOTRANSPLANTATION EXPRESSING HUMAN CD46 AND TBM GENES, IN WHICH PORCINE ENDOGENOUS RETROVIRUS ENVELOPE C IS NEGATIVE AND GGTA1, CMAH, iGb3s AND ß4GalNT2 GENES ARE KNOCKED OUT, AND METHOD FOR PREPARING SAME
#392IMMUNOMODULATORY PROTEINS WITH TUNABLE AFFINITIES
#393Chimeric Antigen Receptor (CAR) Targeting Multiple Antigens, Compositions and Methods of Use Thereof
#394EXOSOME COMPRISING STABILIZED RNA THERAPEUTICS
#395USE OF CD9 AS A BIOMARKER AND AS A BIOTARGET IN GLOMERULONEPHRITIS OR GLOMERULOSCLEROSIS
#396PROTEASE-ACTIVATING CD45-GATE CAR
#397TIGIT- AND LIGHT-BASED CHIMERIC PROTEINS
#398CS1 ANTIBODY AND ANTI-CS1-CAR-T CELLS
#399COMPOSITIONS FOR TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA
#400LOCKR-MEDIATED RECRUITMENT OF CAR T CELLS
#401ANTIGEN RECOGNIZING RECEPTORS TARGETING CD371 AND USES THEREOF
#402METHODS AND COMPOSITIONS FOR INHIBITING ADAM8 BIOLOGICAL ACTIVITIES
#403METHOD OF TREATMENT
#404GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD73
#405EXTRACELLULAR VESICLES DERIVED FROM ACTIVATED CAR-T CELLS
#406COMPOSITIONS AND METHODS FOR TARGETED IMMUNOMODULATORY ANTIBODIES AND FUSION PROTEINS
#407Humanized antibody specific for CD22 and chimeric antigen receptor using the same
#408SIRP alpha-CD70 FUSION PROTEIN AND METHODS OF USE THEREOF
#409MULTI-EPITOPIC CONSTRUCT
#410DAF-MCP CHIMERIC PROTEINS, PROCESS TO MANUFACTURE THE SAME AND USE OF THE CHIMERIC PROTEIN FOR TREATING PATHOLOGICAL CONDITIONS INVOLVING THE COMPLEMENT SYSTEM
#411Compositions and methods for internalizing enzymes
#412CD20 THERAPIES, CD22 THERAPIES, AND COMBINATION THERAPIES WITH A CD19 CHIMERIC ANTIGEN RECEPTOR (CAR)- EXPRESSING CELL
#413CHIMERIC ANTIGEN RECEPTORS WITH CD20 SAFETY SWITCH
#414BISPECIFIC OR-GATE CHIMERIC ANTIGEN RECEPTOR RESPONSIVE TO CD19 AND CD20
#415METHODS AND REAGENTS FOR CHARACTERIZING CAR T CELLS FOR THERAPIES
#416ANTI-CD117 ANTIBODIES AND USES THEREOF
#417TWO CHIMERIC ANTIGEN RECEPTORS SPECIFICALLY BINDING CD19 AND IGKAPPA
#418CCL21 AND CHECKPOINT INHIBITORS FOR THE TREATMENT OF CANCER
#419Medicine for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein
#420COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS BEARING HER2 EXON 21 INSERTIONS
#421Methods of sensitizing cancer to immunotherapy
#422Enveloped Virus Resistant to Complement Inactivation for the Treatment of Cancer
#423Glycated CD59 peptides, their preparation, and uses thereof
#424NOVEL BISPECIFIC CD3/CD20 POLYPEPTIDE COMPLEXES
#425RECEPTORS PROVIDING TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY
#426METHODS FOR SCREENING FOR CANCER TARGETS
#427Exosome-targeted DNA vaccine
#428LAMP constructs
#429GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE
#430Methods and compositions for natural killer cells
#431ENGINEERED CD47 EXTRACELLULAR DOMAIN FOR BIOCONJUGATION
#432POLIOVIRUS RECEPTOR (PVR/CD155) KNOCKOUT CELLS DERIVED FROM RD (HUMAN RHABDOMYOSARCOMA) CELL LINE BY CRISPR
#433NON-HLA MATCHED HUMANIZED NSG MOUSE MODEL WITH PATIENT-DERIVED XENOGRAFT
#434NON-HLA MATCHED HUMANIZED NSG MOUSE MODEL WITH PATIENT-DERIVED XENOGRAFT
#435CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA AND METHODS OF USE THEREOF
#436MESOTHELIN CARS AND USES THEREOF
#437Methods of use of soluble CD24 for treating lupus nephritis
#438MODULATORS OF CELL SURFACE PROTEIN INTERACTIONS AND METHODS AND COMPOSITIONS RELATED TO SAME
#439COMPOSITIONS AND METHODS FOR TREATING MUSCULAR DYSTROPHY AND RELATED DISORDERS
#440METHODS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND USES THEREOF
#441Rodent animals expressing human CR1
#442Methods of Use of Soluble CD24 for Neuroprotection and Remyelination
#443mRNA combination therapy for the treatment of cancer
#444MODIFIED IMMUNE CELLS EXPRESSING FLAGELLIN POLYPEPTIDE
#445Protein M fusion proteins and uses
#446Genetically engineered T cells with regnase-1 and/or TGFBRII disruption have improved functionality and persistence
#447Genetically engineered t cells with Regnase-1 and/or TGFBRII disruption have improved functionality and persistence
#448Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor T cells against T cell lymphomas and leukemias
#449COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES
#450Expression of novel cell tags
#451Therapeutic anti-CD9 antibody
#452CD22-SPECIFIC T CELL RECEPTORS AND ADOPTIVE T CELL THERAPY FOR TREATMENT OF B CELL MALIGNANCIES
#453Anti-human kallikrein-2 (hK2) chimeric antigen receptor (CAR) and methods of use thereof
#454Innocuous, structured scaffolds for structure-based amyloid disease vaccines and antigens
#455BIFUNCTIONAL ANTI-PD-1/SIRPA MOLECULE
#456METHODS OF TREATING SENSITIZED PATIENTS WITH HYPOIMMUNOGENIC CELLS, AND ASSOCIATED METHODS AND COMPOSITIONS
#457Breast and ovarian cancer vaccines
#458MATERIALS AND METHODS FOR TREATING CANCER
#459Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof
#460BTLA fusion protein agonists and uses thereof
#461Combination Therapy for Cancer
#462Composition and Method for Regulating Migration of Immune Cells
#463Genetically engineered t cells with regnase-1 and/or TGFBRII disruption have improved functionality and persistence
#464METHODS FOR PROTECTING PORCINE FETUSES FROM INFECTION WITH PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS (PRRSV)
#465NOVEL RECOMBINANT BI-FUNCTIONAL FUSION PROTEIN, PREPARATION METHOD THEREFOR AND USE THEREOF
#466FUSION PROTEINS AND METHODS OF TREATING COMPLEMENT DYSREGULATION USING THE SAME
#467Genetically engineered hematopoietic stem cells and uses thereof
#468MODIFIED T CELL, PREPARATION METHOD THEREFOR AND USE THEREOF
#469Constructs for chimeric antigen receptors
#470NKG2D-FC FOR IMMUNOTHERAPY
#471TACI-FC FUSION PROTEINS AND USES THEREOF
#472Targeting CD24-Siglec Interactions for Treating Subjects with Prediabetes or Diabetes
#473Targeting CD24-Siglec Interactions for the Treatment and Prevention of Nonalcoholic Steatohepatitis
#474Method of increasing tumor killing activity of macrophages or monocytes comprising chimeric antigen receptor
#475NOVEL CONSTRUCTS FOR CHIMERIC ANTIGEN RECEPTORS
#476Siglec transgenic mice and methods of use thereof
#477METHODS AND COMPOSITIONS FOR TRANSDUCING LYMPHOCYTES AND REGULATING THE ACTIVITY THEREOF
#478Immunomodulatory fusion proteins and uses thereof
#479Target-specific extracellular vesicles
#480Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer
#481QUADRICISTRONIC SYSTEM COMPRISING A HOMING RECEPTOR AND CHIMERIC ANTIGEN RECEPTOR FOR STABLE GENETIC MODIFICATION OF CELLULAR IMMUNOTHERAPIES
#482METHODS FOR THE TREATMENT OF DANON DISEASE AND OTHER DISORDERS OF AUTOPHAGY
#483Extracellular vesicles comprising engineered fusion proteins
#484Recombinant Fusion Proteins Targeting P-selectin, and Methods of Use Thereof for Treating Diseases and Disorders
#485SIRPalpha-41BBL fusion protein and methods of use thereof
#486Artificial synapses
#487Compositions and methods for modulating LAIR signal transduction
#488Integral membrane protein display on poxvirus extracellular enveloped virions
#489CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) AND CD22 CAR COMBINATION THERAPIES
#490Breast and ovarian cancer vaccines
#491Nucleic acid for treating mite allergy
#492METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS
#493Tn-MUC1 Chimeric Antigen Receptor (CAR) T Cell Therapy
#494Methods of treating age-related and inflammatory diseases
#495GENE THERAPIES FOR LYSOSOMAL DISORDERS
#496Ligand Matched Transcription Control, Control Devices, and Solute Carriers
#497METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS
#498COMPOSITIONS AND METHODS FOR T CELL ENGINEERING
#499METHOD FOR PROVIDING INFORMATION ON THERAPEUTIC REACTION OF CANCER IMMUNOTHERAPY AND KIT USING SAME
#500Expression of novel cell tags
#501Use of semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastasis
#502CHIMERIC MOLECULES
#503Methods for screening for cancer targets
#504Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein
#505Enhanced antigen presenting ability of RNA car T cells by co-introduction of costimulatory molecules
#506Genetically engineered hematopoietic stem cells and uses thereof
#507Recombinant cell surface markers
#508Chimeric antigen receptor
#509POLYPEPTIDE USEFUL IN ADOPTIVE CELL THERAPY
#510Anti-EGFR1-PD1 targeted/immunomodulatory fusion protein
#511ENDOGLIN POLYPEPTIDES AND USES THEREOF
#512USE OF INTERLEUKIN-7 AND CHIMERIC ANTIGEN RECEPTOR (CAR)-BEARING IMMUNE EFFECTOR CELLS FOR TREATING TUMOR
#513Modified T lymphocytes comprising a CD52 antibody-inducible caspase and methods of apoptosis
#514ENGINEERED PHAGOCYTIC RECEPTOR COMPOSITIONS AND METHODS OF USE THEREOF
#515CHIMERIC ANTIGEN RECEPTORS
#516ENHANCED PRODUCTION OF IMMUNOGLOBULINS
#517Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof
#518MATERIALS AND METHODS FOR TREATING CANCER
#519Compositions and methods for targeted cytokine delivery
#520METHODS AND COMPOSITIONS FOR TREATING VIRAL INFECTIONS
#521CHIMERIC RECEPTORS TO STEAP1 AND METHODS OF USE THEREOF
#522CONSTRUCTS TARGETING AFP PEPTIDE/MHC COMPLEXES AND USES THEREOF
#523Immune cells with DNMT3A gene modifications and methods related thereto
#524TWEAK-receptor agonists for use in combination with immunotherapy of a cancer
#525Tissue targeted immunotolerance with a CD39 effector
#526Methods of use of CD24 for the prevention and treatment of leukemia relapse
#527CHIMERIC ANTIGEN RECEPTORS (CAR)-EXPRESSING CELLS AND COMBINATION TREATMENT FOR IMMUNOTHERAPY OF PATIENTS WITH RELAPSE REFRACTORY ADVERSE GENETIC RISK AML
#528CHIMERIC ANTIGEN RECEPTORS BASED ON SINGLE-DOMAIN ANTIBODIES AND METHODS OF USE THEREOF
#529LAMP CONSTRUCTS COMPRISING ALLERGENS
#530COMPOSITIONS AND METHODS FOR INHIBITION OF LINEAGE SPECIFIC ANTIGENS
#531PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS RESISTANT ANIMALS
#532ENGINEERING OF IMMUNE CELLS FOR EX VIVO CELL THERAPY APPLICATIONS
#533OFF-THE-SHELF STEM CELL AND IMMUNE CELL, AND A PHARMACEUTICAL COMPOSITION INCLUDING THE SAME
#534PROCESS FOR PRODUCING A T CELL COMPOSITION
#535BIVALENT CHIMERIC ENGULFMENT RECEPTORS AND USES THEREOF
#536CD112 variant immunomodulatory proteins and uses thereof
#537CHIMERIC ANTIGEN RECEPTORS WITH MYD88 AND CD40 COSTIMULATORY DOMAINS
#538Non-human animals having a humanized signal-regulatory protein gene
#539Human Betacoronavirus Lineage C and Identification of N-Terminal Dipeptidyl Peptidase As Its Virus Receptor
#540Antibodies and chimeric antigen receptors specific for ROR1
#541SOLUBLE COMPLEMENT RECEPTOR TYPE I VARIANTS AND USES THEREOF
#542Genetically engineered hematopoietic stem cells and uses thereof
#543IMMATURE DENTAL PULP STEM CELLS AND METHODS OF USE TO TREAT BONE MARROW FAILURE
#544Multivalent pharmacophores for high avidity and overexpressed-target specific binding and uses thereof
#545Genetically engineered hematopoietic stem cells and uses thereof
#546Genetically engineered hematopoietic stem cells and uses thereof
#547VECTORS
#548SIRPalpha-4-1BBL variant fusion protein and methods of use thereof
#549CAR T cells that target B-cell antigens
#550Peptidic TGF-beta antagonists
#551Affinity purification of engineered extracellular vesicles
#552CELL SORTING SYSTEMS AND METHODS OF USE
#553Major histocompatibility complex-based chimeric receptors and uses thereof for treating autoimmune diseases
#554NUCLEIC ACID FOR TREATING MITE ALLERGY
#555Chimeric antigen receptors targeting BCMA and methods of use thereof
#556PSGL-1 MODULATORS AND USES THEREOF
#557NUCLEIC ACID FOR TREATING CRUSTACEAN ALLERGY
#558Immunoconjugates comprising signal regulatory protein alpha
#559Mouse having a humanized cluster of differentiation 47 gene
#560USES OF CD20-BINDING MOLECULES AND ADDITIONAL THERAPEUTIC AGENTS
#561Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20
#562LYMPHOCYTE ANTIGEN CD5-LIKE (CD5L) MONOMER, HOMODIMER, AND INTERLEUKIN 12B (P40) HETERODIMER AGONISTS AND METHODS OF USE THEREOF
#563Compositions, methods and kits for treating complement related disorders
#564NK CELL EXPANSION AND USES THEREOF
#565Biomarkers for Diagnosis and Prognosis of Corneal Ectatic Disorders
#566NKG2D-IG fusion protein for cancer immunotherapy
#567NEUTROPHIL SUBTYPES
#568PEPTIDE LIGANDS FOR BINDING TO CD38
#569COMBINATION THERAPY OF A CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY AND A KINASE INHIBITOR
#570Recombinant protein targeting PD-1 and TGFß
#571Multispecific antigen-binding molecules binding to a target and an internalizing effector protein that is CD63 and uses thereof
#572Pathogen-resistant animals having modified CD163 genes
#573Anti-CD20 antibody and uses thereof
#574Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
#575Genetically modified mouse that expresses humanized PD1 and PD-L1 proteins
#576CHIMERIC ANTIGEN RECEPTOR SPECIFIC FOR TUMOR CELLS
#577GENETICALLY ENGINEERED T CELLS HAVING IMPROVED PERSISTENCE IN CULTURE
#578Constructs having a SIRP-alpha domain or variant thereof
#579COMPOSITIONS AND METHODS OF IMMUNOTHERAPY TARGETING TIGIT AND/OR CD112R OR COMPRISING CD226 OVEREXPRESSION
#580INTRACELLULAR DELIVERY OF TARGET-SILENCING PROTEIN
#581RNA TRANSCRIPTION VECTOR AND USES THEREOF
#582CD137 binding fibronectin type III domains
#583ENGINEERED IMMUNE EFFECTOR CELLS AND USE THEREOF
#584PD-L1 binding fibronectin type III domains
#585EXPRESSION VECTORS FOR CHIMERIC ENGULFMENT RECEPTORS, GENETICALLY MODIFIED HOST CELLS, AND USES THEREOF
#586Cellular immunotherapy compositions and uses thereof
#587CELL-TARGETING MOLECULES COMPRISING PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CARBOXY-TERMINAL MOIETIES
#588Immunoregulatory protein-siRNA complex having anticancer activity
#589Gene therapies for lysosomal disorders
#590Chimeric inhibitor molecules of complement activation
#591Biomarkers for cancer therapeutics
#592EXOSOME TARGETING OF CD4+ EXPRESSING CELLS
#593Cell-Mediated Exosome Delivery
#594Methods and devices for complexing target entities
#595Protein engineered extracellular vesicles
#596METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS
#597METHODS OF USE OF SOLUBLE CD24 FOR THERAPY OF RHEUMATOID ARTHRITIS
#598TIGIT- and light-based chimeric proteins
#599Variant AIM
#600METHODS AND COMPOSITIONS FOR PROMOTING OPC DIFFERENTIATION AND REMYELINATION USING RECEPTOR ASSOCIATED PROTEIN (RAP)